MediPharm Labs Corp.
MEDIF
$0.0573
$0.00183.24%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.47% | 19.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.47% | 19.75% | |||
| Cost of Revenue | -20.81% | 20.94% | |||
| Gross Profit | 5.12% | 17.31% | |||
| SG&A Expenses | 6.02% | -22.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -27.56% | -160.35% | |||
| Total Operating Expenses | -11.75% | -2.14% | |||
| Operating Income | -10.63% | 85.37% | |||
| Income Before Tax | 78.13% | 39.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 78.13% | 39.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 78.13% | 39.37% | |||
| EBIT | -10.63% | 85.37% | |||
| EBITDA | -114.17% | 107.48% | |||
| EPS Basic | 80.00% | 38.78% | |||
| Normalized Basic EPS | -100.00% | 93.33% | |||
| EPS Diluted | 80.00% | 38.78% | |||
| Normalized Diluted EPS | -100.00% | 93.33% | |||
| Average Basic Shares Outstanding | 0.80% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||